Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study
| Autor: | Lolowa Alswaidan, Abin Thomas, Gahdah Mardawi, Nour Shamas, Rahaf Ali Alqahtani, Laila Carolina Abu Esba |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty Coronavirus disease 2019 (COVID-19) NSAIDs 030106 microbiology Ibuprofen Pharmacy 03 medical and health sciences 0302 clinical medicine Internal medicine Oxygen breathing medicine Risk of mortality 030212 general & internal medicine Prospective cohort study Original Research business.industry Hazard ratio COVID-19 Odds ratio COVID-19 outcomes Infectious Diseases business medicine.drug |
| Zdroj: | Infectious Diseases and Therapy |
| ISSN: | 2193-6382 2193-8229 |
| DOI: | 10.1007/s40121-020-00363-w |
| Popis: | Introduction Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes. Methods We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVID-19 were included. Information on NSAID use was collected through a telephone questionnaire, and patients were followed up for COVID-19 infection outcomes, including death, admission, severity, time to clinical improvement, oxygen requirement and length of stay. Results Acute use of ibuprofen was not associated with a greater risk of mortality relative to non-use (adjusted hazard ratio [HR] 0.632 [95% CI 0.073–5.441; P = 0.6758]). Chronic NSAID use was also not associated with a greater risk of mortality (adjusted HR 0.492 [95% CI 0.178–1.362; P = 0.1721]). Acute ibuprofen use was not associated with a higher risk of admission compared to non-NSAID users (adjusted odds ratio OR 1.271; 95% CI 0.548–2.953). NSAID users did not have a significantly longer time to clinical improvement or length of stay. Conclusion Acute or chronic use of ibuprofen and other NSAIDs was not associated with worse COVID-19 disease outcomes. Electronic supplementary material The online version of this article (10.1007/s40121-020-00363-w) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|